Mayo Clinic Laboratory and Pathology Research Roundup: October 14
Share this:
The research roundup provides an overview of the past week’s research from Mayo Clinic Laboratories consultants, including featured abstracts and a complete list of published studies and reviews.
Featured Abstract
A Phase Two Study of Pembrolizumab Combined with Chemoradiotherapy as Initial Treatment for Anaplastic Thyroid Cancer.
Anaplastic thyroid cancer (ATC) has poor prognosis with median overall survival ~6 months. We previously reported high PD-1/PDL-1 staining in ATC, raising the possibility of the productive application of the immunotherapeutic pembrolizumab. However, finding pembrolizumab to have anecdotally limited single-agent activity in ATC, we sought to alternatively define whether pembrolizumab might synergistically combine with chemoradiotherapy as initial ATC therapy. Via Thyroid.
Published to PubMed This Week
- Uterine Leiomyoma.
Mayo Clinic Proceedings - 78-Year-Old Woman with Intermittent Chest Pain and Palpitations.
Mayo Clinic Proceedings - Male Breast Cancer in the United States: Treatment Patterns and Prognostic Factors in the 21st Century.
Cancer - In Vivo Assessment of High-Molecular-Weight Polyethylene Core Suture Tape for Intra-Articular Ligament Reconstruction: An Animal Study.
The Bone and Joint Journal - Transthyretin Amyloidosis: Putting Myopathy on the Map.
Muscle and Nerve - Sinonasal Mucosal Vasculature in Yellow Nail Syndrome and Chronic Rhinosinusitis with or without Polyps.
International Forum of Allergy and Rhinology - Correction To: Hybridization Capture-Based Next-Generation Sequencing Reliably Detects FLT3 Mutations and Classifies FLT3-Internal Tandem Duplication Allelic Ratio in Acute Myeloid Leukemia: A Comparative Study to Standard Fragment Analysis.
Modern Pathology
